Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Recruiting · NCT07252232 · Registry updated 2026-09-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Phase 3 | 2026-09-23 | NCT07252232 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Revolution Medicines, Inc. | 18 |
78 results · Page 1 of 4
Research sites
Swipe the table sideways for more columns.